IOL Chemicals and Pharma Ibuprofen manufacturing facilities in Barnala clears USFDA inspection

Mumbai: IOL Chemicals and Pharmaceuticals (IOLCP) recently received a communication from US Food and Drug Administration (USFDA) with respect to an inspection conducted by the USFDA of Ibuprofen manufacturing facilities located at Trident Complex, Mansa Road in Barnala of Punjab.

The inspection was carried out between August 5 to 9, 2019.

Read Also: USFDA rebukes Torrent Pharma management of inadequacy, violations at multiple sites

The USFDA has concluded that inspection is 'closed' under 21 CFR part 20.64(d)(3), IOL Chemicals said in a filing with BSE.

IOLCP Pharma was established in 1986 and is a significant player in the Organic chemicals space. It has a wide presence across various therapeutic categories like Pain Management, Anti-diabetic, Anti-hypertensive, Anti Convulsants, etc.

Read Also: Sanofi opens digital biologics manufacturing facility in the US